BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Penazzato M, Townsend CL, Rakhmanina N, Cheng Y, Archary M, Cressey TR, Kim MH, Musiime V, Turkova A, Ruel TD, Rabie H, Sugandhi N, Rojo P, Doherty M, Abrams EJ; PADO4 participants. Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list. Lancet HIV 2019;6:e623-31. [PMID: 31498110 DOI: 10.1016/S2352-3018(19)30193-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Orkin C, Apea V. International Women's Day—how can I help? The Lancet HIV 2022. [DOI: 10.1016/s2352-3018(22)00060-1] [Reference Citation Analysis]
2 Lee C, Sapasap J, LaRochelle J, Smith RO, Badowski ME. Antiretroviral Therapy in Children and Adolescents: A Look Into Modern Single Tablet Regimens. J Pediatr Pharmacol Ther 2021;26:783-94. [PMID: 34790067 DOI: 10.5863/1551-6776-26.8.783] [Reference Citation Analysis]
3 Low A, Teasdale C, Brown K, Barradas DT, Mugurungi O, Sachathep K, Nuwagaba-Biribonwoha H, Birhanu S, Banda A, Frederix K, Payne D, Radin E, Wiesner L, Ginindza C, Philip N, Musuka G, Sithole S, Patel H, Maile L, Abrams EJ, Arpadi S. Human Immunodeficiency Virus Infection in Adolescents and Mode of Transmission in Southern Africa: A Multinational Analysis of Population-Based Survey Data. Clin Infect Dis 2021:ciab031. [PMID: 33912973 DOI: 10.1093/cid/ciab031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Malebari AM, Kara A, Khayyat AN, Mohammad KA, Serrano DR. Development of Advanced 3D-Printed Solid Dosage Pediatric Formulations for HIV Treatment. Pharmaceuticals 2022;15:435. [DOI: 10.3390/ph15040435] [Reference Citation Analysis]
5 Montanha MC, Fabrega F, Howarth A, Cottura N, Kinvig H, Bunglawala F, Lloyd A, Denti P, Waitt C, Siccardi M. Predicting Drug-Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling. Clin Pharmacokinet 2021. [PMID: 34635995 DOI: 10.1007/s40262-021-01067-1] [Reference Citation Analysis]
6 Yin DE, Ludema C, Cole SR, Golin CE, Miller WC, Warshaw MG, McKinney RE Jr; PENPACT-1 (PENTA 9 / PACTG 390) Study Team. Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors. PLoS One 2020;15:e0242405. [PMID: 33226999 DOI: 10.1371/journal.pone.0242405] [Reference Citation Analysis]
7 Morin S, Lallemant M, Garcia-Prats A, Lewis L, Watkins M, Giaquinto C, Valentin M, Penazzato M, Reeder JC; Global Accelerator for Paediatric Formulations (GAP-f). Pediatric COVID-19 Therapeutics: Seizing the Right Research and Development Opportunities to Accelerate Access for Children. Pediatr Infect Dis J 2021. [PMID: 34784302 DOI: 10.1097/INF.0000000000003331] [Reference Citation Analysis]